Myriad gets $14.2 million for pathogen drug/diagnostic:
This article was originally published in Clinica
Myriad Genetics has been awarded a five-year, $14.2m contract by the US National Institutes of Health for work that could lead to the development of products that focus on microorganisms and pathogens. The Salt Lake City, Utah firm says it will use its expertise to characterise pathogen-host protein interactions in an effort to discover targets for the next generation of vaccines, therapeutics and diagnostics. Protein interaction and validation data will be made available to the research and development community through the Proteomics Research Program Administrative Center. Myriad says it retains the rights to commercialise diagnostic and therapeutic targets discovered from the project.